diabetestalk.net

Medtronic Ipro Patient Log Sheet

Medtronic-garmin Deal Gives Wearables New Mhealth Capabilities

Medtronic-garmin Deal Gives Wearables New Mhealth Capabilities

Medtronic-Garmin Deal Gives Wearables New mHealth Capabilities The deal to integrate Garmin's personal activity trackers with Medtronic's remote patient monitoring platform gives mHealth wearables new value as a home telehealth platform for providers. -Medtronic has announced another integration with a popular consumer-facing fitness wearable, adding weight to efforts to combine remote patient monitoring with health and wellness. The Ireland-based medical technology giant last week announced a partnership with Garmin, combining the latters vivofit series activity trackers with the Medtronic Care Management Services (MCMS) RPM platform through the Garmin health software development kit. The integration is designed to combine activity measurements from Garmin wearables with the MCMS platform for both chronic care and post-discharge treatment plans, giving healthcare providers a better idea of what their patients are doing at home. The Evolving Role of mHealth in Medication Management and Adherence "Remote patient monitoring is at its best when technology and care coordination can work together seamlessly," Sheri Dodd, vice president and general manager of Medtronic Care Management Services, said in a press release . "Garmin activity trackers have the features and long battery life that will help make at-home monitoring easier for patients. We are excited to bring this unique integration into our industry-leading services to help enhance the healthcare and post-discharge recovery support care providers can give to their patients, especially those living with chronic conditions." Medtronic, long one of the bigger players in the diabetes care management market, announced its interest in activity bands last November with a partnership with Fitbit . That deal connected patien Continue reading >>

Endocrine Society Reading Room | Use Of Cgm In Type 2 Diabetes A Subject Of Debate | Medpage Today

Endocrine Society Reading Room | Use Of Cgm In Type 2 Diabetes A Subject Of Debate | Medpage Today

Use of CGM in Type 2 Diabetes a Subject of Debate This Reading Room is a collaboration between MedPage Today and: Justin B. Echouffo Tcheugui MD, PhD Brigham and Women's Hospital Boston, MA There has been increasing interest in the use of continuous glucose monitoring (CGM) technology in the management of diabetes. The two main approaches to the clinical use of CGM in the evaluation of glycemic control include a professional (retrospective) use by providers and a personal (real-time) use by patients. While the use of CGM has traditionally been accepted in type 1 diabetes, its indications have been less clear for type 2 diabetes patients. Irrespective of the type of diabetes, various endocrine expert societies only recommend the professional CGM, and for only two purposes. One purpose is to detect hypoglycemia (silent or asymptomatic) in at-risk patients -- such as those using medications with a high potential for hypoglycemia, or with hypoglycemia unawareness possibly related to diabetic neuropathy. The other purpose is for monitoring blood glucose among patients in whom other means (hemoglobin A1c or fingerstick) are unreliable because of high glycemic variability, such as dialysis patients. The exact frequency at which professional CGMs should be performed is unknown, as is whether patients should be blinded to such an undertaking or not. The implementation of real-time personal CGM has been hindered by two main challenges. First, the cost of real-time CGM is prohibitive since it is not reimbursed, unlike professional CGM. Second, there is a paucity of evidence from randomized clinical trials on the duration and frequency of personal CGM, as well as on its potential beneficial effects on outcomes such as hemoglobin A1C or quality of life among type 2 diabetes patient Continue reading >>

Press Release | Newsroom | Medtronic | Medtronic And Fitbit Partner To Integrate Health And Activity Data Into New Cgm Solution For Simplified Type 2 Diabetes Management

Press Release | Newsroom | Medtronic | Medtronic And Fitbit Partner To Integrate Health And Activity Data Into New Cgm Solution For Simplified Type 2 Diabetes Management

Medtronic and Fitbit Partner to Integrate Health and Activity Data Into New CGM Solution for Simplified Type 2 Diabetes Management New iPro(TM)2 myLog App Collects Data from Continuous Glucose Monitors (CGM) and Fitbit Activity Trackers, Provides Meaningful Insights on How Exercise Impacts Glucose Levels DUBLIN and SAN FRANCISCO - Dec. 7, 2016 - Medtronic plc (NYSE: MDT), the global leader in medical technology, and Fitbit (NYSE: FIT), the leader in the connected health and fitness market, announced a partnership to integrate health and activity tracking for patients living with diabetes and their physicians and care teams. The iPro(TM)2 myLog mobile app will allow patients living with type 2 diabetes to see their glucose levels and physical activity data in one streamlined application. The new integration and partnership brings together Medtronic's sophisticated medical technology with the convenience of automatic activity tracking from Fitbit, which provides meaningful insights into how exercise impacts glucose levels for more effective diabetes care management. "We believe monitoring glucose is a critical element in the management of diabetes and therefore, glucose should be included among other vital signs. As such, it has never been more important to increase the collaboration between healthcare and technology to simplify daily diabetes management for the 29 million patients living with type 2 diabetes in the United States," said Laura Stoltenberg, vice president and general manager of Non-Intensive Diabetes Therapies at Medtronic. "By creating a connection between physical activity and glucose levels, our iPro2 myLog mobile app solution provides new tools and insights, so that physicians can optimize therapy and patients can better understand how to manage their Continue reading >>

Connected Health Newsfitbit And Medtronic Partner To Tackle Diabetes

Connected Health Newsfitbit And Medtronic Partner To Tackle Diabetes

Fitness wearables company Fitbit is partnering with Dublin-based Medtronic to integrate health and activity tracking for patients living with diabetes and their physicians and care teams. The iPro2 MyLog mobile app will let patients living with type-two diabetes see their glucose levels and physical activity data in one streamlined application. The integration and partnership brings together Medtronic's medical technology with the convenience of automatic activity tracking from Fitbit, which provides meaningful insights into how exercise impacts glucose levels for more effective diabetes care management. "We believe monitoring glucose is a critical element in the management of diabetes and therefore glucose should be included among other vital signs," said Laura Stoltenberg, vice president and general manager of non-intensive diabetes therapies at Medtronic. As such, it has never been more important to increase the collaboration between healthcare and technology to simplify daily diabetes management for the 29 million patients living with type-two diabetes in the United States. By creating a connection between physical activity and glucose levels, the mobile app provides tools and insights so physicians can optimise therapy and patients can better understand how to manage their diabetes. By helping people with diabetes implement lasting lifestyle changes, this partnership underscores our commitment to transforming diabetes care, together, for greater freedom and better health," said Stoltenberg. Maintaining and tracking glucose levels is critical to managing diabetes effectively. For people living with type-two diabetes, understanding how exercise affects glucose levels is a critical element to proper glucose management and long-term health. Additionally, many patients Continue reading >>

Professional Continuous Glucose Monitoring In Clinical Practice 2010

Professional Continuous Glucose Monitoring In Clinical Practice 2010

Professional Continuous Glucose Monitoring in Clinical Practice 2010 Texas Diabetes and Endocrinology, Austin, Texas Correspondence to: Thomas C. Blevins, M.D., FACE, Texas Diabetes and Endocrinology, 7144 Valburn Drive, Austin, TX 78731; email address [email protected] Disclosures: The author is part of the speakers' bureaus for Lilly, Amylin, Astra-Zeneca, Novartis, Novo Nordisk, Merck, Minimed Medtronic, GlaxoSmithKline, and Bristol-Myers Squibb. The author has received research support (clinical research) from Lilly, Novo Nordisk, Amylin, and Roche. Copyright 2010 Diabetes Technology Society This article has been cited by other articles in PMC. Professional continuous glucose monitoring (PCGM) is a 35 day test done to evaluate diabetes control. The PCGM test uses interstitial glucose measurements done every 5 min with a glucose-oxidase-impregnated membrane. The PCGM test evaluates glucose control retrospectively with the glucose results being unknown to the patient until the results are downloaded after the testing period. The PCGM test allows the practitioner and patient to evaluate the effect of diet, physical activity, medications, and lifestyle events on glucose control during the 24 h period. Developing a PCGM program at a medical office involves understanding reimbursement issues and having trained staff and a process in place to initiate the test and download and interpret the data. Keywords: continuous glucose monitoring, continuous glucose monitoring system, glucose oxidase, glucose sensor, interstitial glucose, iPro, real-time glucose monitor The advent of home glucose testing technology in the 1970s made urinary glucose testing obsolete. Self-monitoring of blood glucose (SMBG) quickly became a standard in diabetes management. However, SMBG provi Continue reading >>

Medtronic & Fitbit Partner To Connect Activity Data With Continuous Glucose Monitoring

Medtronic & Fitbit Partner To Connect Activity Data With Continuous Glucose Monitoring

Medtronic & Fitbit partner to connect activity data with continuous glucose monitoring A new partnership between Medtronic and Fitbit will allow diabetic patients with continuous glucose monitors to combine that information with activity data collected by their Fitbit, helping patients get more insights into their glucose trends and insulin needs. Since exercise has an effect on glucose levels, its important for those with the condition to track their activity. In the past, this usually meant taking a blood sample, logging the levels, logging activity, and then inputting all of the information manually. Continuous glucose monitors, like the iPro2 Professional Continuous Glucose Monitoring (CGM) system, have been around for a while.These devices measure extracellular glucose levels just beneath the skin, a surrogate for blood glucose levels. Last year, Medtronic combined that with an insulin pump and got FDA approval for the first closed-loop glucose monitoring and insulin delivery system for patients. That system gets us a bit closer to the holy grail of an artificial pancreas. But one thing it doesnt account for well is exercise and activity. Thats left to the user to track and adjust for manually. Now, Medtronics iPro2 myLog mobile medical app automatically combines metrics from Fitbit activity trackers with their data. While that wont generate any automated changes in insulin dosing, it could help users better correlate how physical activity affects their glucose levels and adjust more proactively. There are plenty of health apps and devices that offer people with diabetes a deeper insight into the disease, including smart socks that monitor the temperature of the foot and can sense inflammation. These kinds of devices can help generate a stream of data thats automa Continue reading >>

Medtronic And Fitbit Team Up To Tackle Diabetes

Medtronic And Fitbit Team Up To Tackle Diabetes

Medtronic and Fitbit Team Up To Tackle Diabetes The companies are working together to integrate health and activity tracking technologies to offer a simplified solution for type 2 diabetes management. Shown is a sample pattern snapshot showing the data provided by the iPro2 system. This week Medtronic and Fitbit announced plans to collaborate on an innovative new technology known as the iPro2 myLog, a device that will partner with a mobile app to enable patients with type 2 diabetes to monitor their glucose levels and physical activity data in one simple application. The new partnership aims to bring together Medtronic's innovative medical technology with one of the world's most popular fitness tracking devices. Laura Stoltenberg, vice president and general manager of non-intensive diabetes therapies at Medtronic, said in a press release this week that glucose monitoring has become an essential vital sign to monitor when considering how many people suffer from diabetes. "We believe monitoring glucose is a critical element in the management of diabetes and therefore, glucose should be included among other vital signs," she said. "As such, it has never been more important to increase the collaboration between healthcare and technology to simplify daily diabetes management for the 29 million patients living with type 2 diabetes in the United States. By creating a connection between physical activity and glucose levels, our iPro2 myLog mobile app solution provides new tools and insights, so that physicians can optimize therapy, and patients can better understand how to manage their diabetes." Medtronic designed the technology to record a patient's glucose levels 24 hours a day for up to six days at a time, to help create a profile of information for the user. Together with Continue reading >>

Medtronics New Ipro Monitoring Device Lets Doctors Track Patients More Closely

Medtronics New Ipro Monitoring Device Lets Doctors Track Patients More Closely

Medtronics New iPro Monitoring Device Lets Doctors Track Patients More Closely The Food and Drug Administration has approved the newest continuous glucosemonitoring system from diabetes management device manufacturer Medtronic. TheiPro continuous glucose recorder is a simplified evaluation tool fordoctors that allows them to uncover patterns and potential problems in patientsthat often go undetected with standard glucose measurements, such asfinger-stick meters and HbA1c tests. Medtronic says that the device's small size and improved ergonomics will helpdoctors more easily develop personalized diabetes management programs forcertain patients. These include people who experience dangerous high and lowblood sugar levels, are unaware of hypoglycemia, desire better control, havegestational diabetes or are pregnant. The iPro is attached to a tiny glucose sensor that is inserted just under the skin Once inserted, the recorder automatically measures and stores blood glucose measurements for three days Daily activities such as work, sleep, blood glucose monitoring/finger sticks and exercise continue as usual while patients are wearing the device After three days, the testing is complete and the patient returns to the physician's office where the iPro data, blood glucose meter data and log sheet information are downloaded to a computer Physicians can then generate reports and interpret results with their patients The recorder is small, lightweight and waterproof allowing patients to swim and bathe with confidence The iPro unit attaches to small sensor under the skin. It records blood glucosevariations over a three-day period. Patient return their iPros to their doctors who then download its data to acomputer. Your email address will not be published. Required fields are marked Continue reading >>

Enlite Glucose Sensor | The Minimed 640g System - Medtronic Diabetes Ireland

Enlite Glucose Sensor | The Minimed 640g System - Medtronic Diabetes Ireland

Smaller and more flexible sensor: 80% reduction in size compared to the former Enlite Sensor Features an innovation to the sensor adhesive patch to help reduce skin irritations Reliable sensor to transmitter connection, which can reduce the likelihood of data gaps. In the event of a lost connection between the sensor and the transmitter, the new Guardian 2 Link transmitter can store up to 10 hours of data Insertion is easy with a one button insertion process, a hidden needle during insertion, a 90 degree insertion angle. 85% of patients agreed that insertion with Enlite was pain free** Small & lightweight: 3.5 x 2.8 x 0.7cm (1.4" x 1.1" x 0.3") and less than 7g (1/4 ounce) Sleek thin profile that is shaped to move with you - it won't tug, pull, or pinch Wireless transmission means that it works under any clothing Waterproof -You can wear the transmitter and glucose sensor while swimming, bathing, or showering. Fully immersible, you can wear it to a depth of 2.4 metres (8 feet) for up to 30 minutes If the sensor connection is lost, the transmitter will store up to10 hours of data which will be displayed upon re-connection to the pump The Guardian 2 Link Transmitter is compatible with the MiniMed 640G insulin pump, while the MiniLink Transmitter is compatible with the MiniMed Paradigm Veo System and the Guardian REAL-Time CGM System. Inserting a Guardian2 Link Transmitter & EnliteSensor Watch this video for further instruction on inserting a Guardian 2 Link transmitter and with Enlite glucose sensor. - New Generation Enlite sensor is indicated for adults and children and only intended for use with Medtronic products: MiniMed640G System, MiniMed ParadigmVeoSystem, MiniMedParadigmREAL-Time System, Guardian REAL-Time CGM System, iPro2. - New Generation Enlite sensor is not Continue reading >>

Medtronic Diabetes Hcp - Ipro2

Medtronic Diabetes Hcp - Ipro2

iPro2 Professional CGM has been designed to help you see the big picture. By gainingmore complete insights into your patients' glycaemic profiles, you will be able to make more informed therapy and lifestyle recommendations, which it's expected can lead to improved glucose control for your patients. This is how iPro2 Professional CGM works: You own the devices that are used for blinded or masked collection of glucose data Patients wear the device for 6-7 days and return it to you to download the data Patients do not receive glucose alerts, but only see the CGM data after you have analysed and interpreted the results. Which patients would benefit from Professional CGM? Typically, candidates for Professional CGM are patients with Type 1 or Type 2 diabetes who experience any of the following: Believe they are experiencing the effect of hypo unawareness In addition, candidates will include all pregnant women with Type 1 diabetes, while Professional CGM may also facilitate treatment adherence for pregnant women with Type 2 diabetes or insulin-requiring gestational diabetes. How will health care professionals benefit from iPro2 Professional CGM? Fast and simple process: Starting a patient on an iPro is a quick and easy process. The sensor insertion process takes a few minutes and the patient only needs to be trained in how to record activities in a log book. CareLink iPro: Data recorded by iPro2 is organised into user-friendly reports that help you to quickly evaluate your patients' unique glucose patterns, helping you educate them on how their diet and daily activity affect their glucose levels. Reports can be emailed to you by the patient, or you can remotely download them to your device, so you are fully prepared for a patient appointment. For more information about CareL Continue reading >>

Glycemic Pattern In Diabetic Patients On Hemodialysis: Continuous Glucose Monitoring (cgm) Analysis

Glycemic Pattern In Diabetic Patients On Hemodialysis: Continuous Glucose Monitoring (cgm) Analysis

Glycemic Pattern in Diabetic Patients on Hemodialysis: Continuous Glucose Monitoring (CGM) Analysis Gai M.a Merlo I.a Dellepiane S.a Cantaluppi V.a Leonardi G.a Fop F.a Guarena C.a Grassi G.b Biancone L.a I have read the Karger Terms and Conditions and agree. I have read the Karger Terms and Conditions and agree. Buy a Karger Article Bundle (KAB) and profit from a discount! If you would like to redeem your KAB credit, please log in . Save over 20% compared to the individual article price. Buy Cloud Access for unlimited viewing via different devices Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use * The final prices may differ from the prices shown due to specifics of VAT rules. For additional information: Background/Aims: Recent evidences suggest that hemodialysis (HD) induces glycemic variations in diabetic patients. Continuous glucose monitoring (CGM) devices measure interstitial glucose in a Holter-like' manner thereby improving the glycemic control assessment method. Methods: A CGM device (Medtronic iPRO) was used on 12 diabetic patients with chronic HD for 6 days to assess intra- and extra-dialytic interstitial glucose. Results: In all enrolled patients, HD was associated with a decrease of interstitial glucose values. Intradialytic glucose nadir was 79 mg/dl and it was reached at the third hour after the beginning of the session. At the end of HD, interstitial glucose increased in all patients and a glycemic peak (187 mg/dl) occurred after an average time of 2.5 h. No episodes of nocturnal hypoglycemia occurred. Conclusion: HD is associated with significant intradialytic reduction of glycemia and postdialytic hyperglycemia. CG Continue reading >>

My Week With The Medtronic Ipro Begins!

My Week With The Medtronic Ipro Begins!

D.D. Family Type 1 since 1991, Animas Ping since June 2010 You're fine - that sensor looks 100% normal - a little blood is part of the sensor insertion process (DID YOU LOVE THAT BIG NEEDLE!!!!!) I admit I silently freaked out JUST A LITTLE when I saw that thing! It's HUGE! And I was hoping she'd use one of those launchers but she said she's better at doing it manually. It didn't hurt as much as I'd feared. But I don't know whether I have it in me to do put one of these (or a pump one) into me regularly! I'm one of those people who can't even wax my own leg, haha. (Of course, I would've said the same thing about needles if I were diagnosed just now.) "Anyone who sets out on a journey of self-development will be aided. There will be guides and teachers who appear, and spiritual protectors to watch over the traveller. No test will be given that the traveller does not already have the strength to meet." -- A Teaching of the Sacred Tree Marta, looks the same as the sensor I had on when I borrowed a CGMS last week from my DE, which went strong for the 5 days I borrowed it. It is a bit offputting to see the blood, isn't it! You welcomed me to the forum and I asked what pump you were on which was a bit silly of me sorry. I was on MDI for about 17 years and I found myself nodding my head at your description at the start of the thread, of how you find it. The pump really helped me - but bear with me, I know you probably know this but may not be in a position to be on the pump! (Or just not want to). The reason I mention it is not just because of the ongoing, at the time benefits of using a pump, but because the pump is an incredible took for education and diagnostics about your own blood sugars and I found a lot out. I gained a window into a number of control factors I suspecte Continue reading >>

Medtronic, Fitbit Partner To Integrate Data From Cgm Device, Activity Tracker Into One App

Medtronic, Fitbit Partner To Integrate Data From Cgm Device, Activity Tracker Into One App

Medtronic, Fitbit partner to integrate data from CGM device, activity tracker into one app Medical device maker Medtronic has teamed up with Fitbit to integrate physical activity data with blood glucose levels into one streamlined application. People living with type 2 diabetes who use Medtronic's iPro2 continuous glucose monitoring system and its companion app, iPro2 myLog , will now be able to have their Fitbit data automatically synced to the app, enabling them to easily see the connection between their exercise and glucose levels. For people with this condition, understanding how exercise affects glucose is a critical element to proper diabetes management, but many have been either manually tracking and recording their physical activity or working with several apps at once. Adam Pellegrini, Fitbits vice president of digital health, said the integration of wearable technology with professional diagnostic tools can make the data gleaned from physical activity more accurate and actionable, and that the partnership with Medtronic was a long time coming. There really was a natural desire to help those with type 2 diabetes, who need to check their glucose frequently and be active to maintain their weight, to really have both levels in the same place, Pellegrini told MobiHealthNews in an interview. We wondered: How could Fitbit, which is on the wrist of so many Americans, work with the most credible organization in the diabetes management space? They know diabetes, we know consumers. Creating this dual data visualization platform was our way to do more together. Pellegrini, who was previously head of digital health for Walgreens Boots Alliance before joining Fitbit in August, is responsible for leading the fitness wearable company deeper into the healthcare ecosystem. He Continue reading >>

Medtronic Partners With Fitbit For Diabetes Tracking

Medtronic Partners With Fitbit For Diabetes Tracking

Medtronic partners with Fitbit for diabetes tracking Will integrate the health trackers into its CGMmobile app Medtronic is working with Fitbit to integrate health and activity tracking functions into the new version of its continuous glucose monitoring (CGM) mobile app. The medical technology firm hopes its iPro2 myLog app will provide a simplified way for patients with type 2 diabetes to manage their condition by presenting their glucose and physical activity levels within a single app. Medtronic said its tie-up with Fitbit would provide meaningful insights into how exercise impacts glucose levels for more effective diabetes care management. Laura Stoltenberg, general manager of Non-Intensive Diabetes Therapies at Medtronic, said: "[There] has never been more important to increase the collaboration between healthcare and technology to simplify daily diabetes management for the 29 million patients living with type 2 diabetes in the US. "By creating a connection between physical activity and glucose levels, our iPro2 myLog mobile app solution provides new tools and insights, so that physicians can optimise therapy and patients can better understand how to manage their diabetes. The aim is for the new version of the app, which is available for Apple and Android devices, to provide a better understanding of the impact exercise has on glucose levels, and the partners said MyLog would also make it easier for information to be shared with a patient's healthcare team. Adam Pellegrini, vice president of digital health for Fitbit, said: "We believe the integration of wearable technology with professional diagnostic tools can provide a more accurate and actionable view of a patient's physical activity. "By partnering with Medtronic, we are able to bring the power of Fitbit's au Continue reading >>

Fda Approves Medtronic's Enlite Sensor For Ipro2 Cgm Systems

Fda Approves Medtronic's Enlite Sensor For Ipro2 Cgm Systems

Medtronic announced that the FDA has approved the Enlite Sensor for its iPro2 continuous glucose monitor (CGM). The disposable sensor is can be worn 24 hours a day for up to six days, and both its insertion and wear have been found to be more comfortable than previous sensor models. The iPro2 system, first launched in 2011, features a host of next-generation innovations and allows doctors to gain a better understanding of an individual’s experience with diabetes than A1C tests and standard glucose meter measurements, which only capture a moment in time. By identifying patterns in both hypoglycemic and hyperglycemic excursions over six days of the system’s use, doctors can better form a management strategy to suit an individual patient’s lifestyle. In 2015, Medtronic launched the Pattern Snapshot for the iPro2 CGM. The new, simplified CareLink iPro report — which is presented on one page — includes easy-to-understand data regarding a patient’s glucose patterns, which can be used by doctors as a teaching tool. The Pattern Snapshot identifies the top three priority issues in a patient’s glucose profile and highlights potential causes and solutions. “We fundamentally believe that to improve outcomes for people with diabetes, physicians need advanced insights to optimize therapy and people with diabetes need to understand the context behind glucose fluctuations to drive behavior change,” said Laura Stoltenberg, VP and GM of Non-Intensive Diabetes Therapies at Medtronic, in a recent press release. With the most recent FDA decision, the iPro2 system will now be available with the Enlite Sensor, which is 69 percent smaller than previous Medtronic sensors and features an easier insertion process. Studies and surveys conducted with the Enlite found that 75 perce Continue reading >>

More in blood sugar